Compare WOR & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOR | ADPT |
|---|---|---|
| Founded | 1955 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | N/A | 2019 |
| Metric | WOR | ADPT |
|---|---|---|
| Price | $52.74 | $18.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $59.67 | $16.60 |
| AVG Volume (30 Days) | 137.4K | ★ 1.9M |
| Earning Date | 12-16-2025 | 02-05-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | ★ 150.90 | N/A |
| EPS | ★ 2.13 | N/A |
| Revenue | ★ $1,253,567,000.00 | $252,754,000.00 |
| Revenue This Year | $17.70 | $50.86 |
| Revenue Next Year | $5.30 | $0.53 |
| P/E Ratio | $24.90 | ★ N/A |
| Revenue Growth | 7.43 | ★ 42.57 |
| 52 Week Low | $39.05 | $6.26 |
| 52 Week High | $70.91 | $20.76 |
| Indicator | WOR | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 59.49 |
| Support Level | $52.28 | $16.55 |
| Resistance Level | $54.29 | $19.16 |
| Average True Range (ATR) | 1.27 | 1.00 |
| MACD | 0.13 | 0.18 |
| Stochastic Oscillator | 54.63 | 82.08 |
Worthington Enterprises Inc is a designer and manufacturer of products and services, including manufactured metal products. The company operates under two reportable operating segments: Consumer Products and Building Products. The consumer Products business has a diverse product offering in the tools, outdoor living and celebrations categories, including propane-filled cylinders for torches, handheld torches, specialized hand tools, drywall tools, accessories and gas grills, and others. And the Building Products business engaged in providing pressurized containment solutions, providing critical components in the residential, non-residential, and repair and remodel end markets through essential categories. The company derives majority of the revenue from Building Products segment.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).